German Communications Stock News

Wondering if RWE has quietly turned into one of the more interesting value ideas in European utilities? You are not alone, and the headline numbers only tell part of the story. The stock has climbed 2.7% over the last week, 1.5% over the past month, and is now up a striking 50.8% year to date and 63.0% over the last year. That naturally raises the question of whether the current price still stacks up. Those gains have come as investors refocus on RWE's role in the European energy transition,...

Dr. Ing. h.c. F. Porsche (XTRA:P911) has quietly lagged this year, with the share price down sharply even as earnings and net income have grown. This raises questions about whether the market is overlooking improving fundamentals. See our latest analysis for Dr. Ing. h.c. F. Porsche. The latest pullback, including a 1 week share price return of minus 2.5 percent and a year to date share price return of roughly minus 21 percent, suggests momentum has been fading even as earnings have improved...

Porsche Automobil Holding (XTRA:PAH3) has quietly climbed about 12% over the past month and 18% in the past year, even as its longer term three year and five year returns remain negative. See our latest analysis for Porsche Automobil Holding. That recent 1 month share price return of about 12% looks more like a sentiment shift than a blip, especially given the roughly 18% 1 year total shareholder return against still negative multi year figures. This suggests momentum is rebuilding from a low...

Wondering if Siemens is still a smart buy after its strong run, or if the best days are already priced in? This article unpacks what the current share price really implies about future value. The stock has slipped a modest 0.3% over the last week but is still up 8.1% over 30 days, 24.9% year to date, 27.7% over the past year, and 99.1% over 3 years and 130.9% over 5 years, which naturally raises the question of how much upside is left. Recent attention around Siemens has focused on its...

Bertrandt (XTRA:BDT) has wrapped up FY 2025 with fourth quarter revenue of €235.9 million and a basic EPS of -€0.99, underscoring that the headline story is still about losses rather than profit. Over the past few quarters, the company has seen revenue move from €266.5 million in Q1 2025 to €249.9 million in Q2, €225.6 million in Q3 and then €235.9 million in Q4. EPS stayed negative in each period, keeping margins under pressure and investors focused on how quickly the business can stabilize...

If you are wondering whether Salzgitter is still a smart buy after its big run up, or if the value has already been priced in, this article will help you unpack that question in plain language. The stock has been on a tear, up 36.9% over the last month and 158.2% over the past year, even after a small 1.4% pullback in the last week. Recent moves have been shaped by a mix of themes in the steel and materials space, including renewed interest in European industrials and ongoing attention on...

FORTEC Elektronik AG's ( ETR:FEV ) dividend is being reduced from last year's payment covering the same period to €0.40...

In recent weeks, the European market has experienced mixed performance, with the pan-European STOXX Europe 600 Index ending slightly lower and major stock indexes showing varied results. Amidst these fluctuations and potential rate hikes from the European Central Bank, investors are increasingly on the lookout for small-cap stocks that demonstrate resilience and strong fundamentals. Identifying a good stock in this environment often involves focusing on companies with robust financial metrics...

Fresenius Medical Care (XTRA:FME) has been drifting quietly in recent weeks, but the stock’s mixed performance this year sets up an interesting question for investors: how do its improving profits square with the weaker share price? See our latest analysis for Fresenius Medical Care. Despite a softer 90 day share price return of 6.89 percent and a year to date share price return of 7.47 percent, Fresenius Medical Care’s improving fundamentals and solid three year total shareholder return of...

Key Insights Using the 2 Stage Free Cash Flow to Equity, RENK Group fair value estimate is €81.10 Current share price...

Key Insights Using the 2 Stage Free Cash Flow to Equity, cyan fair value estimate is €4.51 cyan's €2.28 share price...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

BRAIN Biotech AG ( ETR:BNN ) shareholders should be happy to see the share price up 21% in the last quarter. But will...

With its stock down 18% over the past three months, it is easy to disregard Fielmann Group (ETR:FIE). However, stock...

When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") above 18x, you may consider KSB...

Laiqon AG ( ETR:LQAG ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. But the...

artec technologies (ETR:A6T) has had a great run on the share market with its stock up by a significant 21% over the...

Vonovia (XTRA:VNA) is back in focus after the company reshaped its top leadership, bringing in renewables veteran Katja Wünschel as future Chief Development Officer while extending CHRO Ruth Werhahn’s mandate. See our latest analysis for Vonovia. The leadership reshuffle comes as Vonovia’s share price has drifted lower, with a year to date share price return of minus 18.48 percent but a more resilient three year total shareholder return of 25.95 percent. This suggests sentiment is cautious...

Wondering if adidas at €167.05 is a bargain in disguise or a value trap hiding behind a famous brand? This article is going to unpack what the current share price really implies. Despite being down 29.4% year to date and 28.6% over the last year, the stock has bounced 1.7% in the past week and 8.5% over the past month. This hints that sentiment around its 35.7% three year gain might be turning again. Recent headlines have focused on adidas refocusing its brand strategy, pushing performance...

thyssenkrupp nucera KGaA (XTRA:NCH2) just wrapped up FY 2025 with fourth quarter revenue of €182 million and EPS of about €0.01, capping off a year where trailing twelve month revenue came in at €845 million and EPS at €0.04. Over the last six reported quarters, the business has seen revenue move from €237 million in Q3 2024 to a peak of €262 million in Q1 2025 before landing at €182 million in Q4 2025, while quarterly EPS has swung between roughly €0.08 and slight losses. This sets the stage...

Commerzbank (XTRA:CBK) has been on investors radar after a strong run, with the stock up roughly 13% over the past month and more than 130% over the past year. See our latest analysis for Commerzbank. The latest move to a share price of $35.32 caps a remarkable stretch, with a triple digit year to date share price return and a 1 year total shareholder return above 130, signalling strong, persistent momentum rather than a short lived spike. If Commerzbank’s run has you rethinking where the...

Carl Zeiss Meditec AG has reported past full-year 2025 results showing sales of €2,227.65 million, up from €2,066.13 million, while net income eased to €141.21 million and basic EPS from continuing operations declined to €1.61. The company also set an annual dividend of €0.55 per share, as it highlighted strong order entry, a higher share of recurring revenue and accelerating Microsurgery growth, even as margins came under pressure from US tariffs and foreign exchange effects. We’ll now...

BASF (XTRA:BAS) has been quietly grinding higher this month, and that steady climb is catching investor attention. The stock’s recent gains sit against a mixed multi year track record and improving earnings momentum. See our latest analysis for BASF. At around $44.02, BASF’s recent 1 month share price return of just over 5% hints that sentiment is stabilising. A 1 year total shareholder return of roughly 9% points to gradually rebuilding momentum rather than a sharp rerating. If BASF’s slow...

If you are wondering whether Merck KGaA is quietly becoming a bargain or just a classic value trap, you are in the right place to unpack what the market might be missing. Despite being down 15.3% year to date and 12.6% over the last year, the stock has bounced about 6.4% in the past month while barely moving over the last week, which suggests sentiment could be starting to shift. That recent move comes as investors refocus on Merck KGaA's diversified exposure to life science tools,...